ARCUTIS BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Increase (Decrease) in Accounts Payable of -$5.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$11.54M, a 2182.31% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $5.61M, a 1716.50% increase year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $6.73M.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$9.29M, a 242.76% decline year-over-year.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$1.69M, a 176.00% decline from fiscal 2024.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was $2.23M, a 29.28% decline from fiscal 2023.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was $3.15M, a 101.41% increase from fiscal 2022.
- ARCUTIS BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was $1.56M, a 538.78% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$5.92M 10-Q · filed 2026-08-05 | $808.00K derived: sum of 3 quarters · filed 2026-08-05 | -$8.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.61M 10-Q · filed 2026-05-06 | $12.34M derived: sum of 2 quarters · filed 2026-05-06 | $3.06M derived: sum of 3 quarters · filed 2026-05-06 | $3.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $6.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$2.56M derived: sum of 2 quarters · filed 2026-02-25 | -$2.00M derived: sum of 3 quarters · filed 2026-08-05 | -$1.69M 10-K · filed 2026-02-25 |
| 2025-09-30 | -$9.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$8.73M derived: sum of 2 quarters · filed 2026-08-05 | -$8.43M 10-Q · filed 2025-10-28 | -$8.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $554.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $863.00K 10-Q · filed 2026-08-05 | $758.00K derived: sum of 3 quarters · filed 2026-08-05 | $7.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $309.00K 10-Q · filed 2026-05-06 | $204.00K derived: sum of 2 quarters · filed 2026-05-06 | $6.71M derived: sum of 3 quarters · filed 2026-05-06 | $1.55M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.40M derived: sum of 2 quarters · filed 2026-02-25 | $1.24M derived: sum of 3 quarters · filed 2026-02-25 | $2.23M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.34M derived: sum of 2 quarters · filed 2025-10-28 | $2.33M 10-Q · filed 2025-10-28 | $1.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$5.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$4.17M 10-Q · filed 2025-08-06 | -$5.37M derived: sum of 3 quarters · filed 2026-02-25 | -$9.34M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $992.00K 10-Q · filed 2025-05-06 | -$201.00K derived: sum of 2 quarters · filed 2026-02-25 | -$4.17M derived: sum of 3 quarters · filed 2026-02-25 | $768.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$5.17M derived: sum of 2 quarters · filed 2026-02-25 | -$224.00K derived: sum of 3 quarters · filed 2026-02-25 | $3.15M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$3.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $969.00K derived: sum of 2 quarters · filed 2024-11-06 | $4.34M 10-Q · filed 2024-11-06 | $4.53M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $4.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $8.32M 10-Q · filed 2024-08-14 | $8.50M derived: sum of 3 quarters · filed 2025-02-25 | $8.72M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $3.38M 10-Q · filed 2024-05-14 | $3.56M derived: sum of 2 quarters · filed 2025-02-25 | $3.77M derived: sum of 3 quarters · filed 2025-02-25 | -$255.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $182.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $399.00K derived: sum of 2 quarters · filed 2025-02-25 | -$3.63M derived: sum of 3 quarters · filed 2025-02-25 | $1.56M 10-K · filed 2025-02-25 |
| 2022-09-30 | $217.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$3.81M derived: sum of 2 quarters · filed 2023-11-03 | $1.38M 10-Q · filed 2023-11-03 | $3.77M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$4.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.17M 10-Q · filed 2023-08-08 | $3.56M derived: sum of 3 quarters · filed 2024-02-27 | $5.80M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $5.20M 10-Q · filed 2023-05-09 | $7.59M derived: sum of 2 quarters · filed 2024-02-27 | $9.83M derived: sum of 3 quarters · filed 2024-02-27 | $9.32M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $4.63M derived: sum of 2 quarters · filed 2024-02-27 | $4.13M derived: sum of 3 quarters · filed 2024-02-27 | $245.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.73M derived: sum of 2 quarters · filed 2022-11-08 | -$2.15M 10-Q · filed 2022-11-08 | -$154.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$506.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$4.39M 10-Q · filed 2022-08-04 | -$2.39M derived: sum of 3 quarters · filed 2023-02-28 | -$5.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$3.88M 10-Q · filed 2022-05-05 | -$1.89M derived: sum of 2 quarters · filed 2023-02-28 | -$5.12M derived: sum of 3 quarters · filed 2023-02-28 | -$1.62M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.24M derived: sum of 2 quarters · filed 2023-02-28 | $2.26M derived: sum of 3 quarters · filed 2023-02-28 | $5.67M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $270.00K derived: sum of 2 quarters · filed 2021-11-04 | $3.68M 10-Q · filed 2021-11-04 | $2.33M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | $3.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $6.91M 10-Q · filed 2021-08-05 | $5.56M derived: sum of 3 quarters · filed 2022-02-22 | $6.23M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | $3.41M 10-Q · filed 2021-05-06 | $2.06M derived: sum of 2 quarters · filed 2022-02-22 | $2.73M derived: sum of 3 quarters · filed 2022-02-22 | $3.35M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$683.00K derived: sum of 2 quarters · filed 2022-02-22 | -$65.00K derived: sum of 3 quarters · filed 2022-02-22 | -$458.00K 10-K · filed 2022-02-22 |
| 2019-09-30 | $664.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $1.28M derived: sum of 2 quarters · filed 2020-11-05 | $889.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $618.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $225.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$393.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $1.26M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |